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Abstract
The secretion of insulin by the pancreas has been the object of much attention over the past
several decades. Insulin is known to be secreted by pancreatic β-cells in response to hyper-
glycemia: its blood concentrations however exhibit both high-frequency (period approx. 10
minutes) and low-frequency oscillations (period approx. 1.5 hours). Furthermore, character-
istic insulin secretory response to challenge maneuvers have been described, such as fre-
quency entrainment upon sinusoidal glycemic stimulation; substantial insulin peaks
following minimal glucose administration; progressively strengthened insulin secretion
response after repeated administration of the same amount of glucose; insulin and glucose
characteristic curves after Intra-Venous administration of glucose boli in healthy and pre-
diabetic subjects as well as in Type 2 Diabetes Mellitus. Previous modeling of β-cell physiol-
ogy has been mainly directed to the intracellular chain of events giving rise to single-cell or
cell-cluster hormone release oscillations, but the large size, long period and complex mor-
phology of the diverse responses to whole-body glucose stimuli has not yet been coherently
explained. Starting with the seminal work of Grodsky it was hypothesized that the popula-
tion of pancreatic β-cells, possibly functionally aggregated in islets of Langerhans, could be
viewed as a set of independent, similar, but not identical controllers (firing units) with distrib-
uted functional parameters. The present work shows how a single model based on a popu-
lation of independent islet controllers can reproduce very closely a diverse array of actually
observed experimental results, with the same set of working parameters. The model’s suc-
cess in reproducing a diverse array of experiments implies that, in order to understand the
macroscopic behaviour of the endocrine pancreas in regulating glycemia, there is no need
to hypothesize intrapancreatic pacemakers, influences between different islets of Langer-
hans, glycolitic-induced oscillations or β-cell sensitivity to the rate of change of glycemia.
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Introduction
Over the past 40 years or so, several experimenters have focused their attention on the mecha-
nisms and modalities with which pancreatic β-cells secrete insulin in response to glycemic sti-
muli. Starting with the seminal work of Grodsky [1] experiments have been carried out on
explanted animal pancreata, subjected to carefully controlled time-varying glucose concentra-
tions, measuring the resulting insulin secretion [2, 3]. Other experiments have been carried out
on animal models (monkeys [4, 5], dogs [6, 7], minipigs [8], rats [9]) as well as human subjects
[10–15], administering variable amounts of glucose in different ways, and observing the corre-
sponding insulin serum concentrations.
The results of these many experimental procedures have shown that insulin secretion, in
response to glucose stimuli, exhibits a number of diverse and interesting properties, ranging
from pulsatility, oscillations, entrainment to exogenous stimuli, first and second phases of
release, potentiation, etc. Up to now, when mathematical modelers have been confronted with
this diverse array of experimental results, they have concentrated their attention on separate
facets of the overall phenomenon. Among the models available in the recent literature, the dis-
tributed controller model presented in [16] was however able to reproduce both rapid and slow
insulin oscillations, as well as glucose entrainment phenomena: the fundamental idea advanced
in that paper was that when a whole population of (heterogeneous) controllers is considered
(firing units), all of them reacting to the same plasma glucose concentration, then oscillatory
phenomena occur, which closely resemble actual experimental observations, and for the emer-
gence of which no oscillatory forcing function (such as oscillating glycolytic glucose degrada-
tion or an intrapancreatic pacemaker) need to be assumed. It will be shown in the present work
that the same idea can also replicate an extended set of in vivo and in vitro experiments, pro-
vided of course that the model structure is modified in order to reflect the different experi-
ments to be simulated. Indeed, the main result of the present work is to show how a model of
this type can account for a wide range of diverse experimental results, using a single set of
parameters for the human experiments and a single set of parameters for the rodent experi-
ments. While the model does not include any dependency on the rate of change of glycemia, it
will still be shown to reproduce accurately the double phase of insulin release during a pro-
longed glucose stimulus: a first phase of impulsive insulin release, immediately upon glucose
administration, and a second phase of more gradual release, dependent on the potentiation
effect of the secretory units. Both in-vivo and in-vitro experimental results will be reproduced:
in particular, the in-vitro experimental framework under investigation is the one detailed in the
pioneering work of Grodsky [1], still considered a standard benchmark to test mathematical
models aimed at accounting for the biphasic pattern of insulin release (see, e.g. the works by
Bertuzzi, Salinari and Mingrone [17] and by Pedersen et al. [18]).
In addition to its success in replicating such a diverse set of experimental procedures, the
proposed approach complies with established physiology, since a population of rather hetero-
geneous firing units, delivering discrete packets of insulin, is perfectly coherent with the knowl-
edge accumulated on β-cells, known to be heterogeneous in their ability to react to glucose [19]
and consequently to deliver insulin [20, 21]. It was recently shown [22, 23] that this heteroge-
neity is preserved over time and that β-cells are not identical with regard to the cellular mecha-
nisms that are activated by glucose stimulation, since insulin secretion does not take place
simultaneously and at the same rate in all β-cells, nor is it a continuous phenomenon, also
according to Grodsky [1]. The proposed model is thus conceived so that the independent firing
units, while functioning qualitatively in the same way (i.e. obeying equations of the same
form), function quantitatively somewhat differently, since their individual model parameters
(the glycemic threshold at which they fire, the size of the insulin granules they deliver, their
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recovery time from the refractory phase, etc.) are not fixed to a single value for all, but are ran-
domly distributed.
Moreover, besides the aforementioned analogies with β-cell physiology, the mechanistic
behavior of the proposed firing units is similar to that of other cell types in the body (neurons,
cardiac and striated muscle cells [24, 25]): all of these cells exhibit some type of critical behavior
(impulse transmission, contraction, insulin granule release) when sufficiently stimulated; the
critical behavior is then followed by a temporary refractory phase, during which the cell is
unable to respond, before response function is progressively restored again (i.e. response occurs
at progressively lower stimulation thresholds).
The paper is organized as follows: the next section provides an overview of the most impor-
tant properties concerning pancreatic insulin secretion, according to different clinical experi-
ments carried out in the last decades, as well as of the state of the art about modeling this
secretion. Section 3 describes in detail the distributed population model, stressing the points
where its current version differs from the previous version. Section 4 focuses on the experi-
ments the model aims to replicate; a discussion section follows, where numerical results will be
provided. Concluding remarks complete the paper.
Pancreatic insulin secretion: experiments andmodeling
Experimental results carried out in the last decades have shown many and diverse features
associated with insulin secretion. From a physiological viewpoint, insulin secretion is discon-
tinuous at different scales: at the level of a single β-cell, insulin is released as discrete granules,
as the final result of the metabolic-electrical activity of the cell, leading to the characteristic
behavior known as bursting, with a period of tens of seconds from spike to spike (see the work
by Pedersen, Bertram and Sherman [26] and references therein); these simple bursts often clus-
ter in compound bursts, with a period of several minutes [27].
Moreover, insulin levels appear to be naturally oscillating in vivo, even in the fasting subject.
Pørksen et al. [12] argued that pulsatile secretion accounts for 75% of the overall insulin secre-
tion in humans. However, the mechanisms underlying the coordination of the about 1 million
of Langerhans islets scattered in the pancreas (as well as of the thousands of β-cells collected
within each Langerhans islet) to release insulin into short-lived and discrete secretory bursts
were not established. There is electrophysiological evidence for coupling of β-cells within the
same islet [28] and it is known that the oscillatory changes in β-cell membrane potential are
associated with insulin release [29]: pancreatic neural networks have been hypothesized to
modulate and coordinate the pulsatile fashion of the secretion. Indeed, an intra-pancreatic
coordinating mechanism, such as an intra-pancreatic neuronal pacemaker, was suggested fol-
lowing experiments that showed preserved pulsatility of insulin release from the isolated per-
fused pancreas [6, 30–32]. However, it is doubtful that a simple neural network could
adequately explain all aspects of such a pacemaker (see the discussion in the work by Matthews
et al. [33] and references therein for more detail). Moreover, the comparison of in vivo versus
in vitro experiments shows a substantially different pattern of insulin pulsatile secretion [33,
34] (higher frequency in vitro, lower frequency in vivo), thus suggesting some further regula-
tion through circulating substrates.
Experiments have shown that glucose concentration oscillates as well, in a fashion strongly
correlated with insulin oscillations [4, 10, 35–37]. The question thus arises, whether glucose
oscillations are the cause or the consequence of insulin oscillations. Glucose/insulin oscillations
tend in fact to exhibit two characteristic regimens, slow (period approx. 50–150 minutes) and
fast (period approx. 5–15 minutes). It was shown that the amplitude and the regularity of the
spontaneous slow oscillations in insulin serum concentration were increased when subjects
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were administered glucose at a steady state (either by constant enteral feeding [13], meal inges-
tion [38] or constant intravenous infusion [39]). Furthermore, slow oscillations could be
entrained by sinusoidally varying intravenous glucose administration rates [14] at frequencies
somewhat higher or somewhat lower than the naturally occurring spontaneous frequency.
These “ultradian” oscillations have been shown to be substantially independent of the day/
night alternation, according to a set of experiments made on night-workers [40]. They also
appear to be independent of other ultradian rhythms (e.g. REM-NREM sleep cycle) [41]. Fast
insulin serum oscillations could be entrained in their turn by fast pulsing administration of glu-
cose [42], even with amounts of glucose so minute that no variation in glycemia could be
detected [15]. A study on fasting conditions in human beings [43] indicates a substantially sim-
ilar pulsatile pattern according to different fasting periods (10 hours versus 58 hours), with dif-
ferent amounts of overall insulin secretion. In the same paper, another glucose infusion
experiment, producing changes in pulse frequency, was considered suggestive of the presence
of a glucose-sensitive pacemaker.
Another very interesting feature of insulin secretion is the occurrence of potentiation, the
ability of the pancreas to respond with progressively increasing insulin amounts to identical
glucose stimuli, when these are repeated in close proximity over time [1]. The evident biologi-
cal value of potentiation is similar to the biological value of immunologic memory: in the one
as in the other case the organism reacts more strongly towards a repetition of the (potentially
dangerous) stimulus.
A further important feature of insulin secretion, which has attracted considerable mathe-
matical modeling interest, is the biphasic reaction to rapidly increasing glycemias: in the first,
rapid response phase, β-cells secrete what insulin is already docked at the cell membrane in
immediately releasable granules, while in the second, delayed phase, new insulin is progres-
sively mobilized from the interior of the cells, packed into granules, which are then docked at
the membrane and finally released. This biphasic insulin secretion pattern is particularly evi-
dent both in explanted pancreata experiments (starting from the pioneering experiments
reported in [1]) and when normal subjects undergo an Intra-Venous Glucose Tolerance Test
(IVGTT), with an initial insulin serum concentration spike appearing immediately after the IV
administration of the glucose bolus, and a secondary, delayed insulin concentration “hump”
depending on sustained pancreatic secretion in the face of glycemias, which do not immedi-
ately return to normal. In fact, as the subject’s insulin sensitivity declines, e.g. in the progression
from normal to prediabetes to Type-2 Diabetes Mellitus (T2DM), the secondary insulin con-
centration hump is more and more pronounced, given the relative inability of the secreted
insulin to force tissues to dispose of the glucose load, leading to sustained hyperglycemia and
sustained pancreatic stimulation, combined with a reduced storage of the hormone in docked
insulin granules.
Many differential modelling approaches are present in the literature, based on different
mathematical structures and aiming to reproduce different features of the glucose-insulin sys-
tem. In his seminal paper [1], Grodsky offered a summarizing model based on the assumption
that insulin is secreted in a discrete fashion, and showed the qualitative similarity of his model
predictions with the experimental results he had obtained by stimulating explanted rodent pan-
creata. Conceptually, the model assumed distributed thresholds, with readily releasable insulin
stored in small packets, different packets being associated with different thresholds. Insulin
secretion into plasma would occur only when the glucose stimulus exceeded the threshold.
This model managed to account separately for both first and second phase insulin release.
Grodsky’s distributed threshold model was slightly modified in the work by Overgaard et al.
[44], where in vivo experiments were considered to validate it. Active and passive insulin com-
partments were formally defined as the amounts of immediately/not-immediately releasable
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insulin, respectively, computed by integration of Grodsky’s insulin distribution function for a
given glucose level. Another evolution of Grodsky’s work was provided by Pedersen et al. [18],
where the insulin distribution function was associated with the Readily Releasable Pool (RRP)
of granules. The Authors provide a multicompartmental model, including the RRP, the inter-
mediate pool where granules are primed (and unprimed) to get into the RRP, the fused pool
accounting for the insulin secretion rate and a mobilization compartment playing the same
role of potentiation as the provision in Grodsky’s model. The model accounts also for the so
called kiss-and-run phenomenon, when fused granules re-seal instead of being released. In
another work by Pedersen et al. [45] the Authors show that the model previously developed
lends itself to writing the insulin secretion rate as the sum of three terms: one is basal secretion,
independent of glucose; the second term is responsible for first phase release, depending on the
time-derivative of environmental glucose concentration; the third term is responsible for sec-
ond phase release, depending on environmental glucose levels. The glycemia time-derivative
control term (first phase) is supposed to vanish for smaller and smaller RRP’s (e.g. for diabetic
patients). Extensions of the previously cited work by Pedersen et al. [18] have been presented
in successive works again by Pedersen et al. [46, 47] for meal ingestion and IVGTT. In a recent
work by Pedersen and Cobelli [47], a slight modification in the potentiation mechanism was
introduced, with the aim to make the model consistent with available top-down models of
insulin secretion. The consequence is that during the IVGTT the glycemia time-derivative
term may be neglected. The same philosophy has been followed in [48], where three phases of
insulin secretion are considered, similar to those seen in the proportional-integral-derivative
type controllers used in engineering control problems.
A different class of models aims to investigate in detail the granule trafficking that deter-
mines insulin secretion [17]. These models account for granule formation (from proinsulin
and granule material) and for granule diffusion from the reserve pool first into the docked
granules compartment, then into the immediately releasable pool of docked granules, and
finally into the granules fused with the cell membrane. Exogenous glucose plays a role by modi-
fying the diffusion coefficients from the reserve pool into the docked granules compartment,
and those from this last into the immediately releasable pool of docked granules. This model
describes a single β-cell; nevertheless, overall insulin secretion rate is modeled, in the case of a
population of β-cells, by defining the fraction of β-cells responding to glucose as a saturating
function of glucose. The same idea of granule trafficking was expanded by Chen, Wang and
Sherman [49] by adding more intermediate compartments from docking to fusion granules
and by explicitly taking into account calcium dynamics. This last model was slightly modified
by Pedersen and Sherman [50], accounting also for the possibility of exocytosis outside the L-
type calcium microdomains, for granules with a high sensitivity to calcium. Calcium dynamics
is taken, for both models, from [27, 51, 52]. A different molecular model that still exploits the
calcium dynamics of the work by Bertram et al. [27], coupled with glycolysis, is the work by
Pedersen, Bertram and Sherman [26], where intra- and inter-islet synchronization was investi-
gated with the aim to reproduce the pulsatility of insulin secretion. In the work by Stamper and
Wang [53] a recent linear model dealing with 5 compartments of granules is presented.
Other scientists have limited themselves to numerical elaboration of the recorded time-
series data, in order to simplify the identification of relevant insulin pulsatility frequencies.
Their models offer a high-level mathematical synthetic description of (as yet) unknown or
imperfectly understood mechanisms. In this way a formal framework is developed within
which it is then easier to formulate specific questions on segments of the overall mechanism;
typical in this respect are nonlinear ordinary differential equations models [14] or more recent
nonlinear delay-differential equations models [54–56], where a multi-compartment nonlinear
system is used to summarize the observable behavior of low frequency insulin oscillations.
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Models of this type attempt to offer simplified deterministic descriptions of the time course of
observed insulinemia, directly relating it to other whole-body state variables (like glycemia),
without considering in detail the individual effect of the secretory units (pancreatic β-cells, col-
lected in the islets of Langerhans) or the actual molecular mechanisms, which act within the
secretory units themselves.
Much modeling has also been done to represent the short time course of glycemia and insu-
linemia over the few hours following a perturbation experiment: several IVGTT and Oral Glu-
cose Tolerance Test (OGTT) models have been proposed, some with more emphasis on
mechanistic, if simplified, interpretation of the shift of substrates [57–60], some including
empirical representations, in particular of gastrointestinal absorption of orally administered
glucose [61].
None of the aforementioned models is aimed at reproducing the whole framework of clini-
cal experiments reported so far: they were conceived to interpret a specific facet of the overall
phenomenon. On the other hand, it is clear that ideally a model of the endocrine pancreas
should be able to explain its behaviour by reproducing all available observations simulta-
neously. Based on the idea of a population of excitable, independent, slightly different control-
lers, coupled with a simple whole-body model of glucose metabolism and insulin kinetics, the
model proposed in the present work will be shown to be sufficient to reproduce well the results
of several heterogeneous experimental procedures.
Materials and Methods
The model presented here is an extension of [16] where, inspired by the seminal work of
Grodsky [1], control of glucose-stimulated pancreatic insulin secretion is effected by a discrete
set of independent controllers (secretory, or firing units), that is, no direct control is exerted on a
secretory unit either by other units or by neural or endocrine mechanisms, the only connection
among the units being the common input signal represented by blood glucose concentration in
in vivo situations or environment glucose concentration in in vitro experiments, as sensed by
each secretory unit. This is consistent with literature data, which stress the crucial role of glucose
feedback in governing pulsatile insulin secretion [2, 15, 42]. The physiological identification of
the firing unit could be the β-cells scattered in the pancreatic Langerhans islet, or, by choosing a
different level of model granularity, subcellular granules, or, conversely, collections of synchro-
nized β-cells within the islets of Langerhans (the synchronization being essentially due to electri-
cal coupling between neighboring cells) [28, 62]. According to this last interpretation of the
firing unit, the total size of the ejected packet may be considered as the total sum of the insulin
secreted by all β-cells in one islet during a compound burst of excitation [26], i.e. during a fast,
isolated series of depolarizations. In any case, we stress the fact that the precise physiological
identification of the secretory unit is beyond the scope of the present work.
A previous model [16] had been proposed to account for oscillatory phenomena related to
insulin secretion. Here we present a modified version of that model, aiming to encompass a
wider set of experiments. Main differences from [16] involve the potentiation effect, which is
represented by a second order system (instead of first-order), assuming the loading potentia-
tion rate as a function of the delayed glucose concentration (instead of the current one). More-
over, the glucose threshold distribution of the firing units has been identified by suitably
exploiting the experiments in [1] (instead of using a general log-normal distribution).
Modelling the pancreas
It is assumed that each single secretory unit is able to react to circulating glycemia by ejecting a
discrete packet of insulin Jn (pmol/kgBW) if glycemia exceeds that unit’s secretion threshold Bn
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(mM). When a secretory unit releases its insulin packet, it enters a (relative) refractory state,
where further stimulation fails to elicit the release of new hormone. This refractory state is rep-
resented in the model by instantaneously increasing that unit’s secretion glycemia threshold to
a high level Rn (mM) whence, over time, it exponentially decreases towards its resting threshold
value Gn (mM), Gn< Rn. The differential equation associated to Bn is:
dBnðtÞ
dt
¼ anBnðtÞ þ anGn þ ðRn  BnðtÞÞd wðfGðtÞ < BnðtÞgÞð Þ; ð1Þ
where αn (min
−1) is the rate of recovery of sensitivity of the secretory unit, G(t) (mM) is the
external glycemia sensed by all the secretory units, and δ() is a Dirac delta term specifying
instantaneous increase of the threshold to the refractory level Rn, associated with discharge of
insulin, at any time the glucose stimulus G(t) exceeds the controller threshold Bn. In this last
expression, χ is the characteristic function of its argument set. Notice that simply writing in
this equation δ(G(t) − Bn(t)) would indicate that the controller fires only when glycemia exactly
equals its threshold, while the form δ(χ({G(t)< Bn(t)})) indicates that the controller will fire
whenever glycemia equals or exceeds its threshold, which is physiologically more plausible.
Different values of threshold Gn account for different secretory unit behaviors, with low/high
values associated to frequently/seldom firing units. Clearly, the larger is the glycemia G(t), the
larger will be the recruitment of secretory units.
Besides being heterogeneously distributed among the firing units, the releasable insulin
packet is assumed to increase in size following prolonged glucose stimulation. Such phenome-
non is known as potentiation [63, 64], and is represented by the following second-order model:
dJnðtÞ
dt
¼ znðDnðtÞ  JnðtÞÞ  JnðtÞd wðfGðtÞ < BnðtÞgÞð Þ;
dDnðtÞ
dt
¼ knðDnðtÞ  DnÞ þ rn
Ggnðt  tÞ
Ggnðt  tÞ þ Ggnn
;
ð2Þ
where Jn (pmol/kgBW) is the actual size of the packet for the n-th firing unit and Dn (pmol/
kgBW) models the current potentiation function level, towards which Jn asymptotically con-
verges at rate zn (min
−1). The potentiation dynamics (the second equation in Eq (2)) refers to
the size of the insulin packet with kn (min
−1) being the spontaneous decrease rate of the insulin
packet size, ρn (pmol/kgBW/min) the maximal loading potentiation rate, Γn (mM) the glyce-
mia at which islet potentiation proceeds at half its maximal rate. The coefficient γn determines
the progression with which potentiation reacts to circulating glucose concentrations (for small
γn, a moderate potentiation occurs over a wide glycemic range, while for large γn, abrupt poten-
tiation occurs over a restricted glycemic range). It is supposed that the potentiation function
can depend on past values of glycemia, since it is theoretically possible that the glycemic stimu-
lus sensed by the pancreas is delayed, and for this reason a time delay τ (min) has been intro-
duced. Finally, the parameter Dn (pmol/kgBW) is the basal insulin packet size towards which
the n-th firing unit of the n-th controller tends at zero glucose stimulus. For instance, assuming
glycemia to converge to its basal value, Gb, the packet size of a given unit n converges to the
asymptotic value
DnðtÞ !
rn
kn
 G
gn
b
Ggnb þ Ggnn
þ Dn: ð3Þ
As soon as the glucose level in plasma G(t) exceeds the threshold Bn(t) of the n-th unit, the
insulin packet is ejected, and the releasable insulin instantaneously decreases to zero for that
unit. The unit then recharges and insulin is stored, in order to be released when needed.
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Remark 1 The potentiation dynamics is one of the major modifications with respect to
[16]: the parameter Dn had been neglected in the previous model because postulating a zero-
glucose stimulus was not reasonable in in vivo experiments; on the other hand, when aiming
to replicate Grodsky in vitro experiments, based on external glucose stimulation of perfused
pancreata, it becomes necessary to introduce a non-zero Dn. The secretory units, in this case,
have a basal state (say, at t = t0) with each threshold Bn(t0) at the resting value Gn and with
insulin packet size Jnðt0Þ ¼ Dnðt0Þ ¼ Dn. Such a basal value for Dn cannot be equal to zero,
because experimental evidence shows a clear initial peak of insulin release (the so called first-
phase release) at the very beginning of glucose stimulation, even when starting from zero glu-
cose concentration in the perfusate [1].
Finally, insulin secretion into the portal vein is inherently a discontinuous process, driven
by a sequence of Dirac pulses. The Insulin Secretion Rate [ISR (pmol/kgBW/min)] is therefore
given by:
ISRðtÞ ¼
XN
n¼1
JnðtÞd wðfGðtÞ < BnðtÞgÞð Þ: ð4Þ
Modelling the in vivo environment
To validate the effects of the proposed insulin secretion model in experiments on living organ-
isms, the same modelling solution of [16] is adopted, and is briefly below reported for conve-
nience. In a living organism, released insulin appears in circulating blood after having gone
through the filtering and delaying action of the liver. Such a processes is described by the fol-
lowing L-compartmental sub-model:
dQ1ðtÞ
dt
¼ hdQ1ðtÞ  hxQ1ðtÞ þ
XN
n¼1
JnðtÞd GðtÞ < BnðtÞð Þ
dQ2ðtÞ
dt
¼ hdQ1ðtÞ  hdQ2ðtÞ  hxQ2ðtÞ
     
dQLðtÞ
dt
¼ hdQL1ðtÞ  hdQLðtÞ  hxQLðtÞ;
ð5Þ
where Qi (pmol/kgBW) refers to the insulin amount in the i-th compartment, and hd, hx
(min−1) are the transfer and clearance rate constants for insulin passage through the liver sinu-
soids. Simulations (not reported) have shown substantially similar results when coherently
varying the number of compartments and the values of parameters hd and hx. For instance, a
larger number L of compartments may be compensated by faster compartment dynamics
(associated with larger values of hx and hd). This (a posteriori) model unidentifiability is a typi-
cal behavior of so-called€sloppy€models, where a high level of granularity makes it so that
many parameter settings are compatible with the output [65]. Therefore, in order to replicate
the effect of transit through the liver without getting into the details of organ physiology, here
we adopt the solution of a single compartment (L = 1). The sloppiness of the model will be fur-
ther addressed in the Discussion section.
Finally, insulin mass QL enters the plasma insulin distribution space according to the follow-
ing equation:
dIðtÞ
dt
¼ k4IðtÞ þ
hdQLðtÞ
VI
; ð6Þ
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where I(t) (pM) is the serum insulin concentration, k4 (min
−1) is the linear clearance rate con-
stant for insulin and VI (ℓ/kgBW) is the apparent distribution volume for insulin.
To describe the dynamic action of insulin on glycemia, a variant of a simple glucose-insulin
representation has been used (a block-diagram scheme is reported in Fig 1). Such glucose
dynamics was originally introduced by Millsaps and Pohlhausen [66], then incorporated in
many subsequent models of the glucose-insulin system [16, 56, 57, 59, 67, 68]:
dGðtÞ
dt
¼ k1~uðGðtÞÞ  k2IðtÞGðtÞ þ
k3ðtÞ
VG
; ð7Þ
where (i) the first term in Eq (7) describes approximately the (supra-threshold) driving glyce-
mia for urinary glucose elimination:
~uðGÞ ¼ 0; G < Gu;
G Gu; G  Gu:
ð8Þ
(
with k1 (min
−1) the apparent insulin-independent renal elimination rate for glucose, occurring
at glycemias greater than the threshold Gu (mM); (ii) the second term is the insulin-dependent
glucose uptake, with k2 (min
−1pM−1) the rate of glucose uptake by tissues per pM of serum insu-
lin concentration; (iii) the third term k3(t) (mmol/kgBW/min) refers to the net balance between
hepatic glucose output and insulin-independent zero-order glucose tissue uptake (essentially by
the brain), with VG (ℓ/kgBW) the apparent distribution volume for glucose. In order to account
Fig 1. Scheme of the in vivomodel. The pancreas releases at any given time a total quantity J(t) of insulin, sum of the amounts Jn(t) secreted by the single
controllers (represented as circles), depending, for the n-th controller, on the threshold Bn(t) and on the potentiation level Dn(t). Insulin flows from the
pancreas through the portal vein (Q1 compartment) to the liver (Qi compartments), from which a part of the hormone is lost. Insulin then reaches plasma (I is
the plasmatic insulin compartment) and stimulates the uptake of glucose by tissues. Glycemia (G compartment) is raised by glucose hepatic production k3
and high glucemias stimulate the production of insulin, closing the cycle.
doi:10.1371/journal.pone.0142344.g001
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for the noisy time-course of the last term k3, a stochastic model has been written:
k3ðtÞ ¼ k3 þ ~sðxðtÞÞ; ð9Þ
where k3 (mmol/kgBW/min) is a central value for k3(t), ξ(t) (mmol/kgBW/min) is the stochastic
process generated by:
dxðtÞ ¼ axðtÞdt þ bdWt; xð0Þ ¼ x0; a; b > 0; ð10Þ
with ξ0 a random variable, independent of the standardWiener processWt, and ~sðÞ a suitably
defined finite-range function. The parameter a (min−1) is related to the tendency of the process
to return towards zero, while b (mmol/kgBW/min3/2) determines the volatility of the process.
The saturation function ~sðÞ has been introduced in order to prevent negative or unbounded
glucose evolutions, as follows:
~sðxÞ ¼
m; x < m;
x; m  x < M;
M; x  M;
ð11Þ
8><
>:
wherem andM (mmol/kgBW/min) are, respectively, the lower and the upper bound of the sat-
uration function.
The model (for human experiments) can be freely accessed from the website http://biomat1.
iasi.cnr.it/gemini/pulsatile, where parameter values can be chosen by the user.
Modelling the in vitro environment
The glucose-insulin system exhibits a different behaviour when the pancreas is removed from
the living organism and is stimulated to produce insulin by means of externally controlled glu-
cose concentrations. We model the experimental situation described by Grodsky [1], where the
pancreas of fasted rats was removed, together with adjacent spleen, stomach and part of the
duodenum. The preparation was placed onto a perfusion apparatus and glucose was adminis-
tered by infusion pump into the celiac artery according to different patterns: the complete
effluent was then collected from the portal vein every 30 or 60 seconds and Insulin Secretion
Rate (ISR) measured.
In contrast to the in vivo environment, in this case the liver is not present and the metabolic
loop is not closed by tissue glucose uptake.
The in vitro environment is diagrammed in Fig 2: the pancreas releases insulin into the por-
tal vein (P compartment), then the hormone flows into the plasma compartment I and eventu-
ally into the measurement compartmentM. The equations describing this process are:
dPðtÞ
dt
¼
XN
n¼1
JnðtÞd wðfGðtÞ < BnðtÞgÞð Þ  kipPðtÞ; ð12Þ
dIðtÞ
dt
¼ kipPðtÞ  kmiIðtÞ; ð13Þ
dMðtÞ
dt
¼ kmiIðtÞ; ð14Þ
where kip (min
−1) is the apparent transfer rate constant between portal and serum insulin com-
partments, and kmi (min
−1) is the apparent transfer rate constant between serum and measure-
ment compartments. The reason of the choice of three compartments downstream of the
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pancreas is due to the need to replicate the observed shape of the sudden increase of ISR as
shown in Fig 1 of the work by Grodsky [1], during the external administration of a constant
quantity of glucose.
According to [1], the ISR in in vitro experiments is obtained by measuring the amount of
insulin produced during a time interval, and dividing it by the elapsed time (typically, 30 sec-
onds or one minute):
ISRðtÞ ¼ Mðt þ DtÞ MðtÞ
Dt
; Dt ¼ 0:5 min: ð15Þ
In the numerical simulations, the integration time interval has been set to Δt = 0.5 min for
the simulation of the in vitro experiments, and to Δt = 0.1 min the simulation of the in vivo
experiments.
Results
This section shows how a variety of experiments reported in the literature can be faithfully
reproduced by the proposed model. These experimental procedures encompass both in vivo
and in vitro experiments, giving rise to both fast and slow oscillations in insulinemia, and
showing the typical biphasic response of insulinemia when a bolus amount of glucose is rapidly
administered.
It is to be underscored that all the simulations described in the present work have been gen-
erated using the same set of parameter and meta-parameter values, possible changes reflecting
the species of the experimental subject and the mechanics of the experimental procedure itself.
In fact, the simulations assume a generic human subject (whose parameters and meta-parame-
ters are shown in Table 1) or a rat (whose parameters and meta-parameters are shown in
Table 2). Even though the model requires the evolution of thousands or even millions of firing
units, hence thousand or millions of coupled equations, the set of involved (meta)-parameters
is small and the model does not exhibit the sloppiness property, such as usually appears in ODE
molecular models when many reactions/equations are coupled together, with possibly hun-
dreds of independent parameters. This is a crucial point: even though the current model is
composed of thousands or millions of equations, its parameter set is small with respect to the
information content of the experiments and the model is therefore identifiable from available
Fig 2. Scheme of the in vitromodel. Block diagram of the model for the in vitro experiments. B1. . .BN and D1. . .DN are respectively thresholds and
potentiations of the different controllers, while J1. . .JN indicate the amount of releasable insulin for each controller. P represents the portal vein, I is the plasma
insulin compartment,M the measurement compartment. The quantityG(t) is the external glucose concentration.
doi:10.1371/journal.pone.0142344.g002
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data. In other words, in the situation discussed here it is not the case that the high dimensional-
ity of the parameter set easily allows the model to fit any data set. In fact, the contrary is true:
the data sets are so diverse, their morphology is so rich, and the parameter set is so relatively
small, that if the model structure were not correct a good fit would be unattainable.
The aim to reproduce more clinical experiments than the ones considered in [16] led us to
modify some of the equations of the model (such as the ones related to potentiation) and to
perform again the whole process of parameter assessment. The new model (endowed with the
new set of univocally fixed parameters) had of course to faithfully replicate the new experi-
ments as well as the old ones. This fact could not be taken for granted, since the model was
changed: this is the reason why the new simulations performed on the old experiments, that
had already been considered in [16], have also been reported.
From a numerical viewpoint, one important question was how many secretory units should
be considered for experiments on human subjects. To this end, starting from a minimal set of
N = 103 secretory units, we looked at the output variations occurring as N increased over sev-
eral orders of magnitude, like 104, 105, 106, etc. The total amount of available insulin, produced
by the N secretory units, was however kept fixed when increasing N, to make comparisons pos-
sible. The results of our simulations show that no significant changes occur in the output
Table 1. Parameter values for the in vivomodel.
Symbol Units Mean Std. deviation Value
N # – – 100’000
L # – – 1
τ min – – 8
hd min
−1
– – 0.9
hx min
−1
– – 0.5
k1 min
−1
– – 8.57 × 10−3
k2 min
−1pM−1 – – 1.4 × 10−4
k 3 mmol/kgBW/min – – 0.01
k4 min
−1
– – 0.08
VI l/kgBW – – 0.25
Vg l/kgBW – – 0.2
Gb mM – – 4.25
αn min
−1 0.3 0.12 –
Rn mM 1000 50 –
kn min
−1 0.1 0.002 –
Dn pmol/kgBW 0.003 3.6 × 10
−5
–
ρn pmol/kgBW/min 6.5 ×10
−3 2 × 10−6 –
Γn mM 9 0.1 –
γn # 10 0.1 –
ζn min
−1 0.1 0.02 –
ν # – – 2.5137
g1/2 mM – – 9.7697
kga min
−1
– – 0.03
a min−1 – – 0.04
b mmol/kgBW/min3/2 – – 5.56 × 10−4
m mmol/kgBW/min – – −5.56 × 10−3
M mmol/kgBW/min – – 9.44 × 10−2
Gu mM – – 9
doi:10.1371/journal.pone.0142344.t001
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profiles by increasing N beyond 105. This fact allows us to distinguish between the physiologi-
cal meaning of a secretory unit from its numerical simulation meaning. In other words, by con-
sidering as firing units 109 pancreatic β-cells or 106 islets of Langerhans (each possibly working
as a single firing unit due to β-cells synchronization) does not produce appreciably different
results in the corresponding numerical simulations.
A further concern involves the statistical variability among different samples of secretory
units (of same sample size N) from the same population (identified by a single set of meta-
parameters). The simulations have shown no substantial modifications in the main features of
the glucose-insulin evolutions across different same-sized samples drawn from the same popu-
lation, thus supporting the consistency of the numerical approach: the glucose-insulin profiles
are emergent properties of the chosen meta-parameters, rather than occasional results due to
random outliers.
The rremainder of this section is structured as follows: the first part shows the simulation of
in vitro experiments as performed by Grodsky [1]. The second part reproduces slow and fast
insulin oscillations (as performed respectively by Simon et al. [13] and by Pørksen et al. [15]),
as well as the entrainment of the insulinemic signal (as performed by Sturis et al. [14]) in man.
Finally, simulated intra-venous glucose tolerance tests (IVGTTs) are carried out on virtual nor-
mal, pre-diabetic and Type 2 Diabetes Mellitus (T2DM) virtual subjects.
Biphasic insulin secretory response in a perfused rat pancreas: Grodsky
1972
We report here simulations of the experiments performed by Grodsky et al. [1], with different
patterns of glucose concentration stimulating insulin production by explanted, perfused rodent
pancreata. Some preliminary results have been presented in [69].
The mathematical model is described by Eqs (1)–(3) and (12)–(14). Given the number N of
secretory units (in case of pancreata coming from rodent, N has been set to 104), one has a sys-
tem of (3N + 3) ordinary differential equations. The distributions chosen for the parameters,
except the one related to the resting threshold Gn, are independent log-normals (with means
Table 2. Parameter values for the in vitromodel.
Symbol Units Mean Std. deviation Value
N # – – 10’000
τ min – – 0
kip min
−1
– – 0.85
kmi min
−1
– – 4.8
αn min
−1 0.65 0.4 –
Rn mM 1000 50 –
kn min
−1 0.1 0.002 –
Dn pmol/kgBW 0.09 5 × 10
−4
–
ζn min
−1 0.2 0.02 –
ρn pmol/kgBW/min 3.2 ×10
−2 2 × 10−5 –
Γn mM 10 0.1 –
γn # 5 0.05 –
ν # – – 2.5137
g1/2 mM – – 9.7697
kip min
−1
– – 0.8
kmi min
−1
– – 4.8
doi:10.1371/journal.pone.0142344.t002
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and standard deviations reported in Table 2). The distribution of the resting threshold Gn has
been reconstructed from the data in Fig 2 of the original work by Grodsky [1], where the insu-
lin secretion rate stimulated by an exogenous stepwise glucose administration in the range
from 50 mg/dl up to 500 mg/dl is reported. Since the glucose stimulus is delivered starting
from zero resting glycemia, it can be hypothesized that the initial peaks are due to all the recrui-
table secretory units at the given glycemic level: all units should in fact be at their resting value
(Bn(0) = Gn) before the infusion is administered (G(t< 0) = 0). Therefore, Table 3 can be con-
structed, where the Cumulative Distribution Function (depending on the glucose concentra-
tion g), obtained by ordinary least squares fitting, can be empirically inferred as:
FðgÞ ¼ g
n
gn1=2 þ gn
; ð16Þ
with
n ¼ 2:5137; g1=2 ¼ 9:7697 mM: ð17Þ
The derivation of the corresponding probability density f(g) is straightforward:
f ðgÞ ¼ dFðgÞ
dg
¼ ngn1=2
gn1
gn þ gn1=2
 2 : ð18Þ
This density has been plotted in Fig 3: from it Gn samples can be drawn.
The other (meta)-parameters for rodents have been calibrated to best reproduce the follow-
ing five experiments from Grodsky [1].
The first experiment consists of a staircase stimulation with glucose administered at 50 mg/
dl increments every 5 minutes, from 50 mg/dl up to 200 mg/dl. The experiment focuses on the
first phase of pancreatic action, that is the initial spike of ISR. In fact, not enough time passes
between successive glucose administration steps for insulinemia to show a secondary slow
increment. The model reproduces remarkably well the observed results, both as regards the
timing of the spikes, their size increments and the persisting increased insulin secretion rate at
the end of each spike and until the next (due to the irregular activity of larger and larger pro-
portions of the recruitable set of secreting units): compare Fig 4 with Fig 1 in Grodsky [1].
The second experiment shows both rapid and slow phases of insulin release: different con-
stant glucose infusions (50, 100, 150, 200, 300 and 500 mg/dl) are administered and the insulin
secretion rate is measured over 60 minutes. The proposed model replicates accurately this
experiment, as shown in Fig 5, comparable with Fig 2 in Grodsky [1].
The third experiment consists of a sustained, intense glucose stimulation at 300 mg/dl for
60 minutes, followed by removal of any external stimulus for 5 minutes, and final reestablish-
ment of the same level of stimulus. This experiment shows specifically the role played by poten-
tiation: in fact, due to the persisting glucose stimulus, the islet are progressively potentiated
(that is, in the model, Dn(t) increases and consequently the packet size Jn(t) of the n-th secre-
tory unit becomes larger). When the stimulus is removed and then re-administered (before
potentiation is given the necessary time to return to baseline), the peak of ISR is much larger in
Table 3. Percent activation (PA) of pancreatic β-cells subject to different glycemic stimuli, as extracted from Fig 2 in [1].
Glyc. (mg/dl) 50 100 150 200 300 500
PA 2% 18.75% 43.75% 56.25% 75% 100%
doi:10.1371/journal.pone.0142344.t003
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amplitude than the initial one. Fig 6 shows the result of the simulated experiment: comparing it
with Fig 3 in Grodsky [1] the similarity of original and simulated tracings is striking.
The fourth and the fifth experiments show the pancreatic response when external glucose is
administered at a constant trending rate; the fourth experiment consists of a combination of
ramp followed by maintenance of a constant level of glucose concentration, while in the fifth
experiment a continuously increasing stimulus (ramp) is applied. The effect of potentiation is
therefore damped in the first case, due to the fact that, though present during the increasing
phase of the stimulus, it is not further strengthened during the constant administration, when,
conversely, the previously excited secretory units are not able to recover from their refractory
state. This determines the observed drop in ISR. In the last experiment, on the other hand,
since the stimulus is always increasing, the potentiation effect combined with the progressively
larger recruitment of secretory units causes a constant increase in ISR. The results of the simu-
lated experiments are reported in Fig 7, comparable with Figs 4 and 5 in Grodsky [1].
Ultradian oscillations in man: Simon et al. 1987
We will henceforth use a different set of model (meta)-parameters (Table 1) in order to repre-
sent the glucose-insulin system in man. Lacking information on the distribution of firing glyce-
mia thresholds in humans, we adopted, at least provisionally, the same distribution identified
in rats, as represented in Fig 3; regarding the position of the distribution, we suppose it to be
approximately the same in rodents and humans, since it is reasonable that a healthy pancreas
Fig 3. Probability density function of the controller firing thresholdsGn.
doi:10.1371/journal.pone.0142344.g003
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manages normal glycemic levels with a fraction of the available islets (i.e. those which have
Gn < g , with g the daily mean glycemia), leaving the others free to intervene in case of need,
with a large hormone secretion reserve to be used, for instance, after meals.
In this paragraph, the experiment performed by Simon et al. [13] is described and the results
of its in silico reproduction with our model is shown. The experiment shows how slow (ultra-
dian) spontaneous oscillations in insulinemia become more evident when a patient undergoes
continuous, constant enteral feeding.
In [13] the exogenous glucose perturbation was a continuous enteral nutrition of 90 kcal/h,
composed of 50% carbohydrate, 35% fat and 15% protein. Glycemia and insulinemia samples
were collected over a 24-h time-period, with a sampling time of 10 min. Since enteral nutrition
consists in delivering the meal (a mixture of proteins, carbohydrates, fats, vitamins and miner-
als) through a tube directly into the stomach or small bowel, a simple first-order gastro-intesti-
nal tract model has been adopted:
dAðtÞ
dt
¼ kgaAðtÞ þ ventðtÞ; ð19Þ
where A(t) (mmol/kgBW) is the glucose mass in the splanchnic compartment, kga (min
−1) is
the splanchnic glucose absorption rate, and vent (mmol/kgBW/min) is the enteral glucose infu-
sion rate. This input term has to replicate the glucose effectively provided by the administered
enteral nutrition, and for this reason we assume that carbohydrates, proteins and fats either
directly provide glucose, or indirectly (e.g. via Randle’s cycle) spare glucose entry into the
Fig 4. Insulin Secretion Rate at staircase-increasing glucose concentrations, comparable with
Grodsky’s first experiment (Fig 1 in [1]).
doi:10.1371/journal.pone.0142344.g004
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Krebs cycle. Considering Eq (19), plasma glycemia Eq (7) thus becomes:
dGðtÞ
dt
¼ k1uðGðtÞÞ þ k2IðtÞGðtÞ þ
k3ðtÞ þ kgaAðtÞ
VG
: ð20Þ
Fig 5. Insulin Secretion Rate at different levels of constant glucose administration, comparable with
Grodsky’s second experiment (Fig 2 in [1]).
doi:10.1371/journal.pone.0142344.g005
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Regarding the value of the input vent, a rough simplification consists therefore in considering
all administered calories as representing (possibly delayed) glucose administration:
90 kcal=h ’ 22:5 g=h ’ 22; 500
60
mg=min ’ 375 mg=min: ð21Þ
Taking into account an average (male, female) normal body weight of 60 kg, we compute that a
reasonably approximate “glucose” enteral administration rate could be:
ventðtÞ ’ 6:25 mg=kgBW=min ’ 0:035 mmol=kgBW=min: ð22Þ
Following Simon et al. [13], intra-assay coefficients of variation have been assumed for glyce-
mia (= 1%) and insulinemia (5.8%), and both signals have been finally filtered by means of a
three-point moving average low-pass filter.
Fig 8 shows the simulated glycemia (upper panel) and insulinemia (lower panel) of a virtual
patient with (continuous line) and without (dashed line) enteral nutrition. It is evident here
that spontaneous oscillations are dramatically amplified and synchronized by the constant
input, exactly as shown in Fig 1 of Simon et al. [13].
Fig 6. Insulin Secretion Rate for discontinuous constant glucose administration, comparable with
Grodsky’s third experiment (Fig 3 in [1]).
doi:10.1371/journal.pone.0142344.g006
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Ultradian oscillations in man: Sturis et al. 1991
The experiment performed by Sturis et al. [14] also investigates the phenomenon of low fre-
quency (ultradian) oscillations in the insulinemia. In this case the oscillations are generated by
three different patterns of exogenous I.V. glucose infusion, administered separately to the same
subject over 24 h. The first infusion of 6 mg/kgBW/min was aimed at enhancing the spontaneous
glucose/insulin oscillations (like in [13], but by means of intravenous glucose stimulation), allow-
ing their natural frequency to be more easily and precisely determined. The constant infusion
was then replaced by a sinusoidal glucose infusions with amplitude equal to 33% of the mean
infusion rate and periods 20% greater (second infusion) or lower (third infusion) than the natural
period detected during the first, constant infusion. The purpose of the experiment was to show
the entrainment of insulinemia oscillations to the frequency of the administered glucose pattern.
In order to replicate the experiment, the glucose Eq (7) is modified as follows:
dGðtÞ
dt
¼ k1uðGðtÞÞ þ k2IðtÞGðtÞ þ
k3ðtÞ þ kexðtÞ
VG
;
kexðtÞ ¼ kex þ Dex sin
2pt
Tex
 
;
ð23Þ
where kex = 6 mg/kgBW/min. In this context:
Fig 7. Insulin Secretion Rate when a pattern of increasing glucose concentrations is reproduced, comparable with Grodsky’s fourth and fifth
experiments (Figs 4 and 5 in [1]).
doi:10.1371/journal.pone.0142344.g007
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• Δex is set to zero in the first experiment, from which the endogenous period of oscillations
Tend is estimated;
• Dex ¼ 0:33k ex in the last two experiments, with Tex = Tend + 0.2Tend and Tex = Tend − 0.2Tend
in the second and third experiments, respectively.
Fig 9 shows the results of the simulation with our model: the three columns correspond to
the three different experiments, the first row reports the exogenous IV glucose infusion, the
second row reports insulinemia, the third row reports glycemia. It is clear that the model repro-
duces very well the entrainment phenomenon. Please note that the units for the exogenous glu-
cose infusion are cc/hr according to Sturis et al. [14] and the equivalent value of 6 mg/kgBW/
min for a generic 70 kg patient is 126 cc/hr, as shown in Fig 9, upper-left plot.
High frequency oscillations in man: Pørksen et al. 2000
The experiment replicated here is the one performed by Pørksen et al. [15], aiming to investi-
gate high-frequency insulinemia oscillations. Differently from previously described in vivo
Fig 8. Glucose/insulin evolutions with and without enteral nutrition.Glucose (upper panel) and insulin
(lower panel) evolution during a 24h period with (continuous line) and without (dashed line) enteral nutrition.
Compare this figure with Fig 1 by Simon et al. [13].
doi:10.1371/journal.pone.0142344.g008
A Unifying Organ Model of Pancreatic Insulin Secretion
PLOS ONE | DOI:10.1371/journal.pone.0142344 November 10, 2015 20 / 34
experiments, here the attention is focused on relatively large oscillations in insulinemia trig-
gered by I.V. administration of very small amounts of glucose. Pørksen et al. showed in fact
that an I.V. glucose administration of 6 mg/kgBW/min for 1 min every 10 min in healthy sub-
jects induces large, clearly defined pulses of insulin secretion compared with the control state
(i.e. no exogenous glucose administration), where irregular spontaneous high-frequency insu-
lin oscillations occur. Moreover, when the train of glucose impulses has a period around 10
minutes, insulin peaks are entrained at the same frequency as the driving glucose boli.
In order to simulate this experiment, we modify the glucose equation adopted in the Sturis
experiment Eq (23) as follows:
kexðtÞ ¼
ginf ; t 2 ½hTex; hTex þ TiÞ
0; t 2 ½hTex þ Ti; ðhþ 1ÞTexÞ;
h ¼ 0; 1; . . . ; ð24Þ
(
where ginf (mmol/kgBW/min) is the exogenous glucose infusion rate, administered continu-
ously during the first Ti minutes of the pulsing period Tex (min).
According to the protocol used in [15], the pulsing period Tex is fixed to 10 min, with Ti = 1
min, while two different values of ginf have been considered (2 and 6 mg/kgBW/min), compar-
ing the results with the control case, in which no exogenous glucose was administered. Glyce-
mia and insulinemia are sampled every minute.
Results are plotted in Fig 10, where the three rows correspond to an administration of 6, 2
and 0 mg/kgBW/min, respectively, with the columns referring to glycemia and insulinemia
respectively: these figures are to be compared with Fig 1 in [15].
Fig 9. Glucose/insulin evolutions entrained by sinusoidal exogenous glucose administration.Glucose
administration (top row), insulinemia (center row) and glycemia (bottom row) during a 720 min period.
Compare this figure with Fig 1 by Sturis et al. [14].
doi:10.1371/journal.pone.0142344.g009
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In real experiments, the infusion of 6 mg/kgBW/min triggered marked pulsatile insulin
oscillations at the same frequency as the input signal, while the corresponding glycemia neither
showed the same entrainment, nor was visibly affected by the (small) impulses themselves.
Moreover, inputs of 2 and 0 mg/kgBW/min do not induce appreciable responses in either gly-
cemia or insulinemia. All of these features can be seen to be reproduced faithfully by the simu-
lations from the model.
Intra-venous glucose tolerance test (IVGTT) in man
The Intra Venous Glucose Tolerance Test (IVGTT) is a standard in-vivo experiment used to
study insulin sensitivity and pancreatic response to a glucose stimulus. In a standard IVGTT,
after a period (three days) of a standard composition diet (55% carbohydrate, 30% fat, 15%
protein), with at least 250 g carbohydrates per day, subjects undergo the test in the morning
Fig 10. Glucose/insulin concentrations during high frequency minimal stimulation.Glucose (left panels) and insulin (right panels) evolution during a
1h30’ period with 6 (upper panels), 2 (center panels) and 0 (lower panels) mg/kg/min intravenous glucose administration. Compare this figure with Fig 1 by
Pørksen et al. [15].
doi:10.1371/journal.pone.0142344.g010
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after an overnight fast. A standard IVGTT (without either Tolbutamide or insulin injections) is
accomplished by rapidly injecting (within one to four minutes) in an arm vein, at time 0 (0’), a
solution containing glucose in a quantity ranging from 0.3 to 0.5g Glucose/kg Body Weight.
Plasma glucose and insulin concentrations are measured from a contralateral arm vein at -30’,
-15’, 0’, 2’, 4’, 6’, 8’, 10’, 12’, 15’, 20’, 25’, 30’, 35’, 40’, 50’, 60’, 80’, 100’, 120’, 140’, 160’ and 180’.
In the present study the trends of plasma glucose and insulin concentrations over time, follow-
ing an IVGTT with 0.36g glucose/kgBW, were simulated by the model (Eqs 1 to 12). In order
to test the robustness of the model in reproducing this type of experiment, responses to the test
of hypothetical subjects with different glucose tolerance states were simulated: a Normal Glu-
cose Tolerance (NGT) subject, an Impaired Fasting Glucose (IFG) subject, an Impaired Glu-
cose Tolerance (IGT) subject, an IFG+IGT subject and a Type 2 Diabetes Mellitus (T2DM)
subject. The above conditions are determined on the basis of the glucose trend over time
recorded following a 75g glucose load (oral glucose tolerance test, OGTT). The ability of the
organism to maintain normal glucose homeostasis is indeed dependent on three tightly related
processes: insulin secretion by pancreatic cells; stimulation of glucose uptake by splanchnic
(liver and gut) and peripheral (primarily muscle) tissues; suppression of hepatic glucose output
[70]. In the normal situation (NGT) fasting glycemia remains below 5.6 mM and glycemia
returns to below 7.8 mM within 2 hours of the oral load. When a defect in glucose homeostasis
arises, depending on the type of impairment, pathological conditions develop. The IFG condi-
tion is characterized by abnormal suppression of Hepatic Glucose Production (HGP) (central
insulin resistance) and hence abnormal fasting plasma glucose (between 5.6mM and 6.9mM).
IGT patients have insufficient tissue glucose uptake after load (peripheral insulin resistance)
and present with 2-hour plasma glucose after oral glucose administration ranging between
7.8mM and 11mM. The associated IFG+IGT state occurs when both the above abnormalities
are simultaneously present. The T2DM stage is characterized by substantial decompensation
produced by insufficient insulin secretion in the face of either central or peripheral insulin
resistance. T2DM is thus defined as either abnormal fasting plasma glucose (>7mM) or abnor-
mal post-prandial glucose levels (>11mM), or both [71]. All the above conditions have been
reproduced by suitably changing the parameter values used for the NGT scenario (the same set
of model parameters adopted for previous in vivo experiments reported in Table 1), as reported
in Table 4. Figs 11 to 15 show plasma glucose and insulin concentrations over time following
the glucose bolus in the five simulated normal and pathophysiological conditions. In Fig 11 the
time-course of the two state variables is reported for NGT: this time-course is very close to the
average glycemia and insulinemia time course observed during IVGTT in healthy patients
[59]. Following a sudden increase in glycemia, insulin is secreted in two phases: a first phase
(in the very first few minutes after the beginning of the experiment) and a second phase
(between 10 and 20 minutes after the glucose bolus). Insulin is secreted consistently with
observed glucose levels and normal glycemia is soon restored at basal glucose levels. The model
parameter k2 represents the (peripheral) insulin sensitivity index, which in normal subjects is
Table 4. Parameters varying values for diseased patient undergone an IVGTT.
Par. NGT IFG IGT IFG+IGT T2DM
k2 1.4 × 10
−4 1.4 × 10−4 1.4 × 10−4  0.65 1.4 × 10−4  0.65 1.4 × 10−4  0.3
k 3 0.01 0.01  1.6 0.01 0.01  1.6 0.01  1.6
μ(ρn) 6.5 × 10
−3 6.5 × 10−3  0.5 6.5 × 10−3  0.5 6.5 × 10−3  0.25 6.5 × 10−3  0.05
mðDnÞ 3 × 10−3 3 × 10−3 3 × 10−3 3 × 10−3 3 × 10−3  0.3
g1/2 9.7697 9.7697 9.7697 9.7697 9.7697 and 4
doi:10.1371/journal.pone.0142344.t004
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of the order of 1 × 10−4 [57, 59]. Parameter k3 represents instead HGP as a consequence of gly-
cogenolysis and gluconeogenesis. In absence of central, hepatic insulin resistance, high plasma
insulin levels suppress both mechanisms; this means that an IFG patient should present with
increased HGP, i.e. with a higher k3 value, set therefore in the simulations to 1.6 times the NGT
reference value. Fig 12 reports the trend of plasma glucose and insulin concentrations following
an IVGTT in an IFG patient. Apart from a fasting glucose concentration higher than that
observed in normal subjects (caused by a higher value of the parameter k3), the two profiles are
not dissimilar from those characterizing NGT subjects. Fig 13 shows an IGT patient, whose
insulin sensitivity index k2 was set at 65% of the normal value. In this case glucose still eventu-
ally decreases towards normal values as a consequence of the higher amounts of secreted insu-
lin (see the bottom panel of Fig 13).
The problem of the effects of the two different types of insulin resistance on insulin secre-
tion has been tackled in different studies. Most of the studies aiming at estimating insulin secre-
tion capacity performed OGTTs, while a limited number of studies performed both OGTTs
and IVGTTs. Findings are controversial. Some studies report a decrease in Acute Insulin
Response (AIR) after IVGTT (that is a decreased first-phase insulin secretory response) in
both isolated IFG and IGT compared with NGT [72–74]. Investigations in Pima Indians have
shown that, with regard to the AIR after intravenous glucose injection, IFG subjects have more
severe defects than those with isolated IGT [75]. However, Faerch et al. [76] found that abso-
lute first-phase insulin secretion during IVGTT was decreased in IFG but not in IGT compared
with NGT. In the work by Abdul-Ghani, Tripathy and De Fronzo [77], subjects with isolated
Fig 11. IVGTT experiment for an NGT patient. Simulated glycemia (upper panel) and insulinemia (lower
panel) for a Normal Glucose Tolerance patient (NGT) during an Intravenous Glucose Tolerance Test
(IVGTT).
doi:10.1371/journal.pone.0142344.g011
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IFG manifested a decrease in first-phase insulin secretory response to intravenous glucose and
subjects with IGT had severe defects in both early- and late-phase insulin responses to intrave-
nous glucose. However it is known that in NGT subjects, the amount of insulin secreted in
response to glucose is inversely correlated with peripheral insulin sensitivity [78–81]. Reduced
insulin sensitivity, therefore, determines an increased plasma insulin response to any given glu-
cose stimulus. Simulations in Figs 12 and 13 show this kind of mechanism: in the early stages
of these pathophysiological conditions the pancreas reacts to higher, sustained plasma glucose
levels by compensatory increased insulin secretion: normal glucose tolerance, when still main-
tained, becomes critically dependent on the β-cell’s ability to increase its secretion in an
attempt to offset the defects in insulin action [82]. Thus, in patients with impaired glucose tol-
erance and in diabetic patients with mild fasting hyperglycemia (6.1–7.8 mM), plasma insulin
response to glucose is uniformly increased [82]. For both IFG and IGT, the parameter μ(ρn)
was decreased (down to 50% normal) in order express the initial decrement of β-cell efficiency
(the parameter μ(ρn) represents the average maximal loading potentiation rate). The increased
insulin response is however still produced by the system, through the recruitment of a larger
number of secretory units. Fig 14 shows a patient with both types of insulin resistance (parame-
ters k2, k3 and μ(ρn) were all modified as before). Here the second phase of insulin secretion is
lower than that observed for isolated IGT, highlighting a progressive deleterious effect of
chronic hyperglycemia on insulin secretion and insulin action [78], a concept that has been
referred to as glucose toxicity. Finally Fig 15 shows two different scenarios for a T2DM patient,
corresponding to two different hypothetical mechanisms of disease. In both scenarios, besides
more severe defects of the same type as in the IFG+IGT condition, the parameter mð DnÞ is
Fig 12. IVGTT experiment for an IFG patient. Simulated glycemia (upper panel) and insulinemia (lower
panel) for an Impaired Fasting Glucose patient (IFG) during an IVGTT.
doi:10.1371/journal.pone.0142344.g012
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decreased by 70%. This parameter represents the basal insulin packet size. A decrement in μ
(D) impacts on insulin secretion: under this hypothesis the long hyperglycemia has compro-
mised β cell functionality (the pancreas produces less insulin), higher than normal glycemia
levels are observed during the IVGTT and a longer time is necessary to return to basal condi-
tions. That these defects occur is undisputed in the literature. The second scenario however
introduces an additional variation, a decrement of the parameter g1/2 shifting the glycemic
threshold distribution of the controllers to the left. A decrease in this parameter means a faster,
more complete recruitment of β-cells at lower glycemias: under this hypothesis on the mecha-
nism of disease, the first phase response is essentially missing and a more sustained second
phase is necessary to face the sustained higher glycemias.
Discussion
As presented at length in the Introduction, pancreatic insulin secretion has been the object of
many explorative experiments and of several modelling attempts. The model proposed in the
present work improves a previously published similar model [16], with changes to the equa-
tions and with a thorough revision of the parameter values based upon the original Grodsky
results. The main goal of this model is to provide a unified explanation of an array of diverse
experimental procedures.
The basic paradigm of this model is that in the pancreas a multitude of similar, but not iden-
tical, controllers react to the sensed plasma glucose, which acts as the single “coupling” signal.
In this way, our model does not need to hypothesize either a glucose-independent pancreatic
pacemaker, nor a dependency of insulin secretion on the rate of change of glucose
Fig 13. IVGTT experiment for an IGT patient. Simulated glycemia (upper panel) and insulinemia (lower
panel) for an Impaired Glucose Tolerance patient (IGT) during an IVGTT.
doi:10.1371/journal.pone.0142344.g013
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concentration [6, 30–32, 46, 61]. The controllers are assumed to share the same basic response
mechanism, reminiscent of the way other excitable cells and tissues in the body work (e.g. neu-
rons or cardiac muscles cells [24, 25]): each controller fires when circulating glucose concentra-
tion reaches the critical threshold for that controller; upon firing, the controller releases a
discrete packet of insulin into the circulation; after having fired, the controller enters a relative
refractory period, with refractoriness progressively attenuating until the pristine, excitable state
is reached and the controller may fire again. The metabolic loop is closed, in the model, by
hypothesizing simple mechanisms of insulin removal from the circulation and of glucody-
namic insulin effect.
While hundreds of thousands of controllers are represented in the model, the behaviour of
the whole system is determined by specifying only few controller population metaparameters:
these are the characteristics of the distributions from which each controller’s parameters are
randomly sampled (glycemia firing threshold; rapidity of return to normal excitability deter-
mining the length of the refractory period; rate of increase of insulin packet size upon persist-
ing hyperglycemia, etc.). The entire model behaviour depends, in this way, on a small number
of parameters and metaparameters (see Tables 1 and 2), notwithstanding its structural
complexity.
The major contribution of the present work is to show that a model of this type, using a sin-
gle plausible parameter set, may faithfully reproduce a wide array of heterogeneus, morpholog-
ically rich experimental results obtained in man, and that, by introducing modest changes in
parameters, other diverse and characteristic experimental results from ex-vivo animal prepara-
tions are also faithfully reproduced.
Fig 14. IVGTT experiment for an IFG+IGT patient. Simulated glycemia (upper panel) and insulinemia
(lower panel) for a IFG+IGT patient during an IVGTT.
doi:10.1371/journal.pone.0142344.g014
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It should be appreciated that, while it is rather easy to justify qualitatively certain effects on
the basis of a plausible mechanistic interpretation (e.g. it is rather obvious that introducing
some delay into the glucodynamic effect of insulinemia could determine slow oscillations in
glycemia and insulinemia itself), building a single model, which can quantitatively reproduce,
with a single set of parameter values, a whole collection of different and richly structured exper-
imental data sets is a more ambitious endeavour. In fact, no such model has been proposed so
far, to the best of our knowledge.
The model exhibits, first of all, both high-frequency and slow-frequency insulinemia oscilla-
tions. High-frequency oscillations appear to be caused by firing-refractoriness-recuperation
cycles over the subpopulation of controllers whose thresholds are below current glycemias.
Low-frequency oscillations, conversely, appear due to the negative-feedback delay of secreted
insulin inducing increments of tissue glucose uptake.
The model is consistent with clinical observations in predicting an accentuation and syn-
chronization of low-frequency insulinemia oscillations, when glycemia is constantly raised (by
meals or by endo-venous constant glucose infusion). This amplification of response is likely
due to the increased recruitment of secretory units and should in fact disappear or be signifi-
cantly reduced in those diseases (like diabetes mellitus) where the possibility of recruiting a
large number of functional controllers is reduced or absent: this also is in accord with experi-
mental observations.
In this context it should be underscored that, while many models could associate insulin
oscillations with glucose oscillations, the present model predicts accentuated insulin oscillatory
behaviour corresponding with constantly raised glycemias.
Fig 15. IVGTT experiment for an T2DM patient. Simulated glycemia (upper panels) and insulinemia (lower panels) for a Type-2 Diabetes Mellitus patient
(T2DM) during an IVGTT. The left-side panels refer to a virtual patient whose thresholds distribution is the same as in the previous cases (g1/2 = 9.7 mM),
while the right-side panels refer to a virtual patient with g1/2 = 4 mM.
doi:10.1371/journal.pone.0142344.g015
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It has been shown that the impairment of the ability of exogenous glucose stimuli to entrain
insulin oscillations is a highly sensitive manifestation of β-cell secretory dysfunction. This has
been clearly assessed for low-frequency oscillations [83–85] in diabetic and prediabetic
patients, as well as for high-frequency oscillations [86, 87] where comparisons have been car-
ried out on healthy subjects versus T2DM patients, with both large [87] and small [86] glucose
pulses. Further experiments, made by replacing glucose with arginine (which successfully
entrained insulin oscillations in T2DM patients as well) showed that the loss of entrainment is
likely to be a glucose-specific β-cell defect [88]. Loss of glucose entrainment has, in fact, also
been found in in vitro experiments on isolated perfused pancreata of Zucker diabetic fatty rats
[42]. The model agrees with the experiments by Pørksen and colleagues [15]: when minimal
amounts of glucose (undetectable by observation of glycemia) are administered periodically,
high-frequency insulin pulsatility is clearly accentuated and is made to synchronize with the
frequency of glucose administration, even when this is somewhat higher or lower than its natu-
ral frequency. The experiments by Sturis et al. [14], involving entrainment to an oscillating gly-
cemic signal, are also well replicated.
The curves obtained by the model, upon simulated I.V. glucose administration, are typical of
what is clinically observed in IVGTT experiments. In particular, both a primary and a secondary
insulin response are evident and the variation of the shape of the insulinemia response closely
mimics what is observed in the clinical setting, as the parameters quantifying tissue insulin sen-
sitivity, liver glucose output, and pancreatic secretory capacity are varied to reflect Normal Glu-
cose Tolerance, Impaired Fasting Glycemia, Impaired Glucose Tolerance, IFG+IGT and finally
Type 2 Diabetes Mellitus. It is of interest, in this context, that the model predicts differently
shaped curves depending on whether a shift to the left in the controllers threshold distribution
occurs or does not occur as prediabetes worsens and T2DM becomes apparent. This indicates a
potential theory-driven direction for experimentation: since the curves commonly observed in
T2DM patients are more similar to the prediction made by the present model incorporating a
left shift of controller thresholds, does this left-shift actually occur in patients pathophysiology?
The model is able to near-perfectly reproduce the increasing insulin release spikes observed
upon progressively increasing (staircase) glycemic stimulation of ex-vivo rodent pancreas prep-
arations. Moreover, the model reproduces very well the initial spike, fall and progressive
increase connected with the sudden start of constant glycemic stimulation, and also quantita-
tively agrees with the observations as progressively higher levels of glycemia are tested.
The shape and size of the successive peaks determined by discontinuous glucose administra-
tions are also perfectly reproduced: here it is worth noticing that the peak corresponding to the
second (re-started) infusion is substantially larger than the peak at the start of the first infusion,
as is indeed the case experimentally. The responses to ramp-and-cease as well as to progres-
sively increasing glycemia stimulations are also in close accord with the experimental results.
The varied morphology of these response curves derives in a straightforward fashion from the
interplay of controller recovery, controller recruitment and potentiation.
The fact that a single model, with a single (species-specific) set of parameters, is able to rep-
licate such a diverse array of experimental procedures, down to the minute characteristics of
spikes and troughs, of shapes of increasing ramps, of coherent frequency and amplitude
responses to non-oscillating or minimal inputs, justifies the conclusion that the model captures
the essential mechanics of the pancreatic control of glycemia by means of insulin secretion.
This close agreement with a variety of experiments is the result of the model structure, which
closely replicates the actual anatomical and physiological behaviour of the organ. A limitation
of the present model is therefore that its structure is rather complex, even though the (meta-)
parameter set is small. In the future it may be possible that other, more concise formulations
will attain the same level of fidelity.
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For the moment, however, the proposed model appears able to account for such a diversity
of physiological and clinical manifestations that strong support is provided to the theory that
neither pancreatic pacemakers, nor single controller cycling (e.g due to oscillating β-cell glycol-
ysis), nor differential controlling (i.e. ability of the controllers to sense rates of change of glyce-
mia) need to be invoked in order to explain pancreatic insulin secretion.
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